Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

The brand came to develop products specifically designed for dermatologists and skin care professionals to treat patients ...

ZURICH, Jan 8 (Reuters) - Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

including any devices which may directly compete with Roche products. Extra financial resources from the acquisition will go toward recruitment, product improvement, and building more ...

We asked a dermatologist to weigh in on the best moisturizing hacks for every skin type during winter. She suggested products ...

FRANKFURT, Jan 30 (Reuters) - Roche (ROG.S), opens new tab said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year ...

Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange ...

Shares in Swiss pharma giant Roche were more than 1% higher on Tuesday afternoon, following the announcement of positive ...

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy Tecentriq, which aims to ...